Indication intelligence, analysis and sector perception

RegMed Investors’ (RMi) pre-open: bottom, bottom; who is coming off their bottom?

October 29, 2018 8:00am

How much and had how far versus those few who keep tripping?

As the markets are staging a comeback ...

Pre-open indication: 1 BUY

Quarterly Results: BrainStorm Cell Therapeutics (BCLI) Q3 GAAP EPS of -$0.15 misses by $0.03 and $10.8 M of cash – a very short “runway”.

I post about “indication intelligence” devoting my time to collection and analysis of information in the perception of sector vulnerabilities and strengths – it’s more than opinion, some facts in evidence need to be recognized!

Members only. Please login.

35 companies, 1 interpreter!

Insight, foresight and recommendation

What's Happening Today

6 hours 20 min ago
RegMed Investors (RMi) Closing Bell: this week’s trend is an admission that the sector is without pricing sustainability suppressing a value directional

15 hours 22 min ago
RegMed Investors’ (RMi) pre-open: the down draft doesn’t seem to be over

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.